Novo Nordisk rejects Baxter patent claim over Novoeight

May 20, 2015 2:57 PM

6 0

COPENHAGEN Novo Nordisk said on Wednesday it rejected claims by U.S. rival Baxter International that it had infringed patents on drugs to treat the bleeding disorder hemophilia, the Danish company said on Wednesday.

Baxter had said Novo Nordisk's newly launched hemophilia drug Novoeight infringed some of its patents, prompting an investigation from the U.S. International Trade Commision announced on Monday.

Also read: U.S. Supreme Court backs Samsung in smartphone fight with Apple

Read more

To category page

Loading...